For laser and cosmetic consultations
For Dermatology (OHIP)
Just recently Galderma Canada Inc. announced Apprilon™, an innovative, anti-inflammatory rosacea treatment, is now available for prescription in Canada. Apprilon (Doxycycline Modified-Release Capsule, 40 mg) is the first and only oral, once-daily therapy designed specifically to treat the bumps and pimples associated with rosacea, and does not cause complications associated with long-term antibiotic use.
Rosacea affects more than two million Canadians, most commonly individuals with fair skin and between the ages of 30 and 60. Symptoms typically include small red bumps that sometimes contain pus, red or pink patches, and visible tiny broken blood vessels. The most common sites for flare ups include the nose, chin and forehead.
Rosacea can be a painful and embarrassing condition for sufferers to deal with. Apprilon is a unique treatment because of its anti-inflammatory properties. It effectively treats the inflammatory lesions caused by rosacea without displaying antibiotic activity, which will allow me to treat patients for long periods of time without the complications or side effects associated with traditional antibiotic use.
Recent evidence suggests rosacea is primarily an inflammatory condition, not a bacterial infection. Apprilon is the only medication that reduces the inflammatory response in patients with rosacea without producing drug concentrations required to treat bacterial diseases.
Marketed as Oracea™ in the United States, the availability of Apprilon offers another treatment option for acne rosacea sufferers.
This adds a new tool to the tool box. With topicals, oral agents and lasers, Dr. Radin and his team at the Radin Skin Centre can really assist those suffering with this condition.